Publicacions en què col·labora amb Mercedes Iñarrairaegui Bastarrica (27)

2017

  1. Conversion from calcineurin Inhibitor-Based immunosuppression to mycophenolate mofetil in monotherapy reduces risk of de novo malignancies after liver transplantation

    Annals of Transplantation, Vol. 22, pp. 141-147

  2. Immune checkpoint inhibitors for the treatment of hepatocellular carcinoma

    Immunotherapy of Hepatocellular Carcinoma (Springer International Publishing), pp. 51-68

  3. NatB-mediated protein N-α-terminal acetylation is a potential therapeutic target in hepatocellular carcinoma

    Oncotarget, Vol. 8, Núm. 25, pp. 40967-40981

  4. Phase 1–2 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrow–derived endothelial progenitor cells

    Translational Research, Vol. 188, pp. 80-91.e2

2016

  1. Factors related to increased resting energy expenditure in men with liver cirrhosis

    European Journal of Gastroenterology and Hepatology, Vol. 28, Núm. 2, pp. 139-145

2015

  1. Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection

    Molecular Therapy - Methods and Clinical Development, Vol. 2, pp. 15006

  2. Immune monitoring of immunosuppression withdrawal of liver transplant recipients

    Transplant Immunology, Vol. 33, Núm. 2, pp. 110-116

  3. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma

    Liver International, Vol. 35, Núm. 6, pp. 1715-1721

  4. Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation

    Liver International, Vol. 35, Núm. 5, pp. 1590-1596

2014

  1. Comparación de las sondas M y XL para estimar la rigidez hepática por medio de elastografía de transición

    Gastroenterologia y Hepatologia, Vol. 37, Núm. 4, pp. 233-239

  2. Is liver biopsy necessary in the evaluation of a living donor for liver transplantation?

    Transplantation Proceedings

  3. Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension

    HPB, Vol. 16, Núm. 3, pp. 243-249

2013

  1. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma

    Journal of Hepatology, Vol. 59, Núm. 4, pp. 753-761

  2. Increased liver stiffness values in patients with heart failure

    Acta Gastro-Enterologica Belgica, Vol. 76, Núm. 2, pp. 246-250

  3. Locoregional transarterial therapies for hepatocellular carcinoma: Transarterial chemoembolization and radioembolization

    Viszeralmedizin: Gastrointestinal Medicine and Surgery, Vol. 29, Núm. 2, pp. 92-102

  4. Lung cancer screening with low-radiation dose computed tomography after liver transplantation

    Annals of Transplantation, Vol. 18, Núm. 1, pp. 587-592

  5. Prognostic factors and prevention of radioembolization-induced liver disease

    Hepatology, Vol. 57, Núm. 3, pp. 1078-1087

  6. Trial of complete weaning from immunosuppression for liver transplant recipients: Factors predictive of tolerance

    Liver Transplantation, Vol. 19, Núm. 9, pp. 937-944

2012

  1. Efficacy of transjugular intrahepatic portosystemic shunt to prevent total portal vein thrombosis in cirrhotic patients awaiting for liver transplantation

    Transplantation Proceedings

  2. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma

    European Journal of Surgical Oncology, Vol. 38, Núm. 7, pp. 594-601